Author

R. Natesan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

I. A. Asangani· 3 shared A. A. Gudiel· 1 shared A. C. Gladstein· 1 shared A. Schwab· 1 shared B. Parma· 1 shared C. Kumar-Sinha· 1 shared D. C. Wallace· 1 shared D. M. Feldser· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

I. A. Asangani

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling

D. M. Walter, A. C. Gladstein, K. R. Doerig, R. Natesan, S. G. Baskaran, A. A. Gudiel, K. M. Adler, J. O. Acosta, D. C. Wallace, I. A. Asangani, D. M. Feldser

This study shows that SETD2 inactivation in lung adenocarcinoma leads to increased oxidative metabolism and mTORC1 activity, making these tumors sensitive to inhibitors of oxidative respiration and mTORC1.

bioRxiv · Oct 6, 2022 · PreprintCancer Biology

Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1

Q. Deng, R. Natesan, F. Cidre-Aranaz, S. Arif, Y. Liu, R. Rasool, P. Wang, Z. Cramer, M. Chou, C. Kumar-Sinha, K. Weber, K. Eisinger-Mathason, N. Grillet, T. G. P. Grunewald, i. a. asangani

The paper identifies a 32-gene signature specific to Ewing sarcoma and shows that LOXHD1, a stereociliary protein, is a key driver of malignancy through its regulation by EWSR1-FLI1.

bioRxiv · Feb 22, 2021Cancer Biology

Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer

M. A. Siddiqui, P. N. Gollavilli, V. Ramesh, B. Parma, A. Schwab, M. E. Vazakidou, R. Natesan, O. Saatci, I. Rapa, P. Bironzo, H. Schuhwerk, I. A. Asangani, O. Sahin, M. Volante, P. Ceppi

This study identifies thymidylate synthase (TS) as a driver of epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC), linking it to metastasis, chemotherapy resistance, and survival.

bioRxiv · Aug 13, 2020Cancer Biology